Attachment B.docx
DOCX document 19 KB Posted
- Attached to
- 6550--MSI testing reagents Federal contract opportunity
- Solicitation number
- 36C26224Q1285
About this file
This document is a Request for Quotation (RFQ) for MSI testing reagents to be used on the Biocartis Idyla System by the Greater Los Angeles VA Healthcare System. The solicitation, numbered 36C26224Q1285, seeks brand name or equal products with specific salient characteristics, including rapid turnaround time, no sample extraction required, and qualitative detection of mutations in 7 MSI loci. The VA intends to award a single firm-fixed price contract through full and open competition under NAICS code 325413. Offerors must submit quotes electronically by June 14, 2024, and any questions are due by June 7, 2024. The award will be made to the responsible offeror with the lowest priced quotation that meets all the salient characteristics. No gray market items will be accepted, and the contractor must be an authorized dealer or distributor of the proposed products.
View the file
Other files for this federal contract opportunity
| File | Type | Posted |
|---|---|---|
| Attachment A.xlsx | XLSX spreadsheet | |
| 36C26224Q1285.docx | DOCX document |
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Attachment B Brand Name or Equal Description/Requirements:
The Brand Name for the below reagents is Biocartis. See Attachment A for associated annual volumes required by the facility.
| PRODUCT DESCRIPTION |
| PRODUCT # |
| Quantity |
| MSI Assay |
| A0101/6 |
| 52 |
Salient characteristics –
· Supplies and reagents must be 100% compatible with all features, must physically fit without alteration and not void warranty of Greater Los Angeles VA Healthcare System’s Biocartis Idyla System.
· The assay shall be ready-to-made reagent with no reagent preparation required
· The assay shall provide the following MSI testing characteristics:
a) Provide a result between in approximately 150 minutes.
b) No sample extraction required prior to use.
c) Testing volume that can be performed on a minimum of 1 slice of FFPE tissue section.
d) Eliminate use of external quality control.
e) Qualitative detection of mutations in 7 novel MSI loci (ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A, and SULF2).
File details come from the government source that posted it. Updated .